BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24857085)

  • 1. Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy.
    Burstein HJ
    Am Soc Clin Oncol Educ Book; 2014; ():e1-3. PubMed ID: 24857085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer subtypes: morphologic and biologic characterization.
    Masood S
    Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].
    Jerusalem G; Collignon J; Josse C; Schroeder H; Rorive A; Frères P; Lambert F; Koopmansch B; Poncin A; Bours V
    Rev Med Liege; 2015; 70(5-6):269-76. PubMed ID: 26285451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 and Breast Cancer - A Phenomenal Success Story.
    Hayes DF
    N Engl J Med; 2019 Sep; 381(13):1284-1286. PubMed ID: 31502769
    [No Abstract]   [Full Text] [Related]  

  • 7. Precision medicine in breast cancer.
    Naito Y; Urasaki T
    Chin Clin Oncol; 2018 Jun; 7(3):29. PubMed ID: 30056731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in the era of personalized oncology.
    Maitland ML; Schilsky RL
    CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in 2020: what can we expect?
    Horton J
    Cancer Detect Prev; 2006; 30(2):109-10. PubMed ID: 16687217
    [No Abstract]   [Full Text] [Related]  

  • 10. [Targeted based therapies in metastatic breast cancer: future evolution].
    Belmondo L; Montana M; Curti C; Crozet M; Rathelot P; Penot-Ragon C; Vanelle P
    Therapie; 2012; 67(6):491-503. PubMed ID: 23249575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foundations of clinical cancer research: perspective for the 21st century.
    Hersh EM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2551-3. PubMed ID: 9815655
    [No Abstract]   [Full Text] [Related]  

  • 12. Twenty years of systemic therapy for breast cancer.
    Mina L; Sledge GW
    Oncology (Williston Park); 2006 Jan; 20(1):25-32; discussion 32-3, 36, 40. PubMed ID: 16572592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of regional nodal irradiation in breast cancer.
    Haffty BG; Mahmoud O
    Breast J; 2015; 21(1):32-41. PubMed ID: 25418516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and leukemia group B breast committee: decades of progress and plans for the future.
    Hudis CA; Winer EP
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3576s-80s. PubMed ID: 16740788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.
    De Boer R; Beith J; Chirgwin J; Chua S; Colosimo M; Francis P; Green M; Pittman K; White M; Wilcken N; Zdenkowski N; Bell R
    Asia Pac J Clin Oncol; 2014 Jun; 10 Suppl S4():15-25. PubMed ID: 24797446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated patient and tumor genetic testing for individualized cancer therapy.
    Hertz DL; McLeod HL
    Clin Pharmacol Ther; 2016 Feb; 99(2):143-6. PubMed ID: 26537014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forty-five years in oncology, 25 years with Acta Oncologica.
    Glimelius B
    Acta Oncol; 2018 Dec; 57(12):1593-1598. PubMed ID: 30489167
    [No Abstract]   [Full Text] [Related]  

  • 18. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
    Harbeck N
    Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical oncology, history and its future in Iran.
    Mirzania M; Ghavamzadeh A; Asvadi Kermani I; Ashrafi F; Allahyari A; Rostami N; Razavi SM; Ramzi M; Nemanipour G
    Arch Iran Med; 2015 Nov; 18(11):799-805. PubMed ID: 26497380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of breast cancer systemic therapy: the next 10 years.
    Telli ML; Sledge GW
    J Mol Med (Berl); 2015 Feb; 93(2):119-25. PubMed ID: 25566982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.